|Title of study||
Prediction tools for Hodgkin lymphoma patients to weigh benefits and harms of different treatment and survivorship care strategies.
1, 6 November 2020
Prof. dr. ir. F.E. van Leeuwen
Drs. B.D.P. Ta
Nederlands Kanker Instituut/ Antoni van Leeuwenhoek (NKI-AVL)
This study aims to develop prediction tools for risks of late adverse effects for patients with Hodgkin lymphoma (HL), both new patients and survivors, and to develop a decision support tool for new patients to weigh the benefits and harms of specific treatments. Ultimately, the purpose is to facilitate personalized decision making regarding the optimal treatment and thereby improve patient outcomes.